Exemplary Translation to Industry

CMAC has always benefited from strong industry engagement and leadership. An industry led membership organisation was created in 2011 and this has grown and developed over the years. The membership organisation operates under a pre-competitive, collaborative research and development model with senior level company support.

The main industry partners (AstraZeneca, Chiesi, Eli Lilly, Pfizer, Roche, Takeda and UCB) get an individual seat on the CMAC Board and an opportunity to influence the direction of future research and Hub activity. Integral to the CMAC ecosystem are the Tier 2 technology companies. These range from large companies, Siemens and PwC, to micro SMEs. This supportive environment helps translate research into equipment and products. In addition to CMAC members the Hub organises many open events for the broader industry landscape and collaborates with a wide range of additional companies locally, nationally and globally.